A Multicenter Phase I/II Trial of Abiraterone + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Investigator: Charles J. Ryan, MD
Sponsor: Novartis Pharma AG
Location(s): United States
There will be two parts to this clinical research study of Castrate-resistant Prostate Cancer. The purpose of each part is:
- Phase 1: This part of the study will determine what dose of BEZ235 is safe to give with a standard dose of abiraterone acetate and prednisone by administering different doses of BEZ235. This will help to find out what effects, good and/or bad, this combination has on CRPC.
- Phase 2: This part of the study will measure the treatment effect of the combination of BEZ235 and abiraterone acetate/prednisone on CRPC.